IL272060A - Compositions containing cannabinoids and methods of using them - Google Patents
Compositions containing cannabinoids and methods of using themInfo
- Publication number
- IL272060A IL272060A IL272060A IL27206020A IL272060A IL 272060 A IL272060 A IL 272060A IL 272060 A IL272060 A IL 272060A IL 27206020 A IL27206020 A IL 27206020A IL 272060 A IL272060 A IL 272060A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- compositions containing
- cannabinoid analog
- analog conjugates
- containing cannabinoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533894P | 2017-07-18 | 2017-07-18 | |
| PCT/US2018/042707 WO2019018536A1 (en) | 2017-07-18 | 2018-07-18 | COMPOSITIONS CONTAINING CONJUGATES OF CANNABINOID ANALOGUES AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL272060A true IL272060A (en) | 2020-03-31 |
Family
ID=65016693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272060A IL272060A (en) | 2017-07-18 | 2020-01-15 | Compositions containing cannabinoids and methods of using them |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3654971A4 (de) |
| JP (1) | JP2020527589A (de) |
| KR (1) | KR20200031663A (de) |
| CN (1) | CN111065391A (de) |
| AU (1) | AU2018302155B2 (de) |
| CA (1) | CA3070538A1 (de) |
| EA (1) | EA202090116A1 (de) |
| IL (1) | IL272060A (de) |
| MX (1) | MX2020000673A (de) |
| WO (1) | WO2019018536A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3145109A1 (en) * | 2019-06-24 | 2020-12-30 | Diverse Biotech, Inc. | Cannabinoid conjugate molecules |
| CA3157998A1 (en) * | 2019-10-15 | 2021-04-22 | Diverse Biotech, Inc. | Conjugate molecules |
| CN112807301A (zh) * | 2020-12-30 | 2021-05-18 | 福建省中科生物股份有限公司 | 麻类植物提取化合物Cannabiorcol在制备抗肿瘤药物上的用途 |
| US11554184B2 (en) | 2021-03-26 | 2023-01-17 | Vyripharm Enterprises, Inc. | Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases |
| US20220305145A1 (en) * | 2021-03-26 | 2022-09-29 | Vyripharm Enterprises, Inc. | Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm |
| US20220305148A1 (en) * | 2021-03-26 | 2022-09-29 | Vyripharm Enterprises, Inc. | Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754188B2 (en) * | 2003-06-30 | 2010-07-13 | Merck Sharp & Dohme Corp. | Radiolabeled cannabinoid-1 receptor modulators |
| CN101516899B (zh) * | 2006-04-19 | 2016-07-06 | 得克萨斯大学体系董事会 | 细胞成像和治疗的组合物和方法 |
| WO2009029727A1 (en) * | 2007-08-28 | 2009-03-05 | Vanderbilt University | Cannabinoid receptor targeted agent |
| US20120288442A1 (en) * | 2011-05-11 | 2012-11-15 | Atomic Energy Council-Institute Of Nuclear Energy Research | Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis |
| EP2992880A1 (de) * | 2014-09-04 | 2016-03-09 | Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau | Verwendung von Hämoxygenase-1-Induktoren und Cannabinoid-2-Rezeptor oder Delta-Opiod-Rezeptoragonisten bei Entzündungsschmerz |
| GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
-
2018
- 2018-07-18 JP JP2020502993A patent/JP2020527589A/ja active Pending
- 2018-07-18 KR KR1020207004617A patent/KR20200031663A/ko not_active Application Discontinuation
- 2018-07-18 EP EP18835211.6A patent/EP3654971A4/de not_active Withdrawn
- 2018-07-18 CA CA3070538A patent/CA3070538A1/en active Pending
- 2018-07-18 AU AU2018302155A patent/AU2018302155B2/en not_active Ceased
- 2018-07-18 CN CN201880056590.6A patent/CN111065391A/zh active Pending
- 2018-07-18 EA EA202090116A patent/EA202090116A1/ru unknown
- 2018-07-18 MX MX2020000673A patent/MX2020000673A/es unknown
- 2018-07-18 WO PCT/US2018/042707 patent/WO2019018536A1/en unknown
-
2020
- 2020-01-15 IL IL272060A patent/IL272060A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200031663A (ko) | 2020-03-24 |
| CN111065391A (zh) | 2020-04-24 |
| JP2020527589A (ja) | 2020-09-10 |
| EP3654971A4 (de) | 2021-04-21 |
| EA202090116A1 (ru) | 2020-05-14 |
| EP3654971A1 (de) | 2020-05-27 |
| AU2018302155A1 (en) | 2020-02-06 |
| MX2020000673A (es) | 2020-07-29 |
| AU2018302155B2 (en) | 2022-09-15 |
| CA3070538A1 (en) | 2019-01-24 |
| WO2019018536A1 (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2582482B (en) | CASZ compositions and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| EP3595653A4 (de) | Zusammensetzungen von plinabulin und verwendung davon | |
| EP3576782A4 (de) | Konstrukt-peptid-zusammensetzungen und verfahren zur verwendung davon | |
| IL268970A (en) | New preparations and methods | |
| IL272060A (en) | Compositions containing cannabinoids and methods of using them | |
| IL271275A (en) | Preparations containing coronas and their uses | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| GB202201859D0 (en) | Novel methods and compositions | |
| EP3691677A4 (de) | Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL276135A (en) | Preparations and methods of use | |
| IL274166A (en) | Cannabinoid compounds and their uses | |
| ZA202000502B (en) | Cosmetic compositions and methods of use | |
| IL275739A (en) | Preparations for cryopreservation and methods of their use | |
| EP3402443A4 (de) | Vorrichtungen und zusammensetzungen und verfahren zur verwendung davon | |
| IL272834A (en) | Compositions of amantadine, their preparation, and methods of use | |
| IL291730A (en) | Protein-macromolecule conjugates and methods for using them | |
| PL3638278T3 (pl) | Kompozycje neuroprotekcyjne i ich zastosowanie | |
| IL274433B2 (en) | Fulvestrant formulations and methods of using them | |
| EP3635324A4 (de) | Umkehreinfrierungszusammensetzungen und deren verwendung | |
| ZA202007107B (en) | Compositions comprising pcsk9-binding molecules and methods of use | |
| IL274563A (en) | Methods of use and preparations containing dolaglutide | |
| IL261794A (en) | Preparations and methods for using them | |
| IL273904A (en) | Medicinal resin components and methods for their production and use |